These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Neuromyelitis optica positive antibodies confer a worse course in relapsing-neuromyelitis optica in Cuba and French West Indies. Cabrera-Gómez JA; Bonnan M; González-Quevedo A; Saiz-Hinarejos A; Marignier R; Olindo S; Graus F; Smadja D; Merle H; Thomas L; Gómez-García A; Cabre P Mult Scler; 2009 Jul; 15(7):828-33. PubMed ID: 19498017 [TBL] [Abstract][Full Text] [Related]
3. Environmental changes and epidemiology of multiple sclerosis in the French West Indies. Cabre P J Neurol Sci; 2009 Nov; 286(1-2):58-61. PubMed ID: 19520388 [TBL] [Abstract][Full Text] [Related]
4. Neuromyelitis optica in France: a multicenter study of 125 patients. Collongues N; Marignier R; Zéphir H; Papeix C; Blanc F; Ritleng C; Tchikviladzé M; Outteryck O; Vukusic S; Fleury M; Fontaine B; Brassat D; Clanet M; Milh M; Pelletier J; Audoin B; Ruet A; Lebrun-Frenay C; Thouvenot E; Camu W; Debouverie M; Créange A; Moreau T; Labauge P; Castelnovo G; Edan G; Le Page E; Defer G; Barroso B; Heinzlef O; Gout O; Rodriguez D; Wiertlewski S; Laplaud D; Borgel F; Tourniaire P; Grimaud J; Brochet B; Vermersch P; Confavreux C; de Seze J Neurology; 2010 Mar; 74(9):736-42. PubMed ID: 20194912 [TBL] [Abstract][Full Text] [Related]
7. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Bonnan M; Valentino R; Olindo S; Mehdaoui H; Smadja D; Cabre P Mult Scler; 2009 Apr; 15(4):487-92. PubMed ID: 19324982 [TBL] [Abstract][Full Text] [Related]
8. Worldwide prevalence of neuromyelitis optica spectrum disorder (NMOSD) and neuromyelitis optica (NMO): a systematic review and meta-analysis. Bagherieh S; Afshari-Safavi A; Vaheb S; Kiani M; Ghaffary EM; Barzegar M; Shaygannejad V; Zabeti A; Mirmosayyeb O Neurol Sci; 2023 Jun; 44(6):1905-1915. PubMed ID: 36745300 [TBL] [Abstract][Full Text] [Related]
9. Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica. Weinstock-Guttman B; Miller C; Yeh E; Stosic M; Umhauer M; Batra N; Munschauer F; Zivadinov R; Ramanathan M Mult Scler; 2008 Sep; 14(8):1061-7. PubMed ID: 18573816 [TBL] [Abstract][Full Text] [Related]
10. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Hinson SR; McKeon A; Fryer JP; Apiwattanakul M; Lennon VA; Pittock SJ Arch Neurol; 2009 Sep; 66(9):1164-7. PubMed ID: 19752309 [TBL] [Abstract][Full Text] [Related]
11. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Papeix C; Vidal JS; de Seze J; Pierrot-Deseilligny C; Tourbah A; Stankoff B; Lebrun C; Moreau T; Vermersch P; Fontaine B; Lyon-Caen O; Gout O Mult Scler; 2007 Mar; 13(2):256-9. PubMed ID: 17439893 [TBL] [Abstract][Full Text] [Related]
12. NMO-IgG and Devic's neuromyelitis optica: a French experience. Marignier R; De Sèze J; Vukusic S; Durand-Dubief F; Zéphir H; Vermersch P; Cabre P; Cavillon G; Honnorat J; Confavreux C Mult Scler; 2008 May; 14(4):440-5. PubMed ID: 18208892 [TBL] [Abstract][Full Text] [Related]